CRA experts advised two parties during both the CMA’s investigation and CAT Appeals, assessing the economic evidence and providing expert testimony on what prices could be considered excessive (or, to the contrary, consistent with competitive outcomes) in the UK market for Liothyronine tablets.
CRA Competition economists contribute to article-by-article commentary on the EU Foreign Subsidies Regulation
It gives the European Commission far-reaching powers to scrutinize financial contributions from non-EU governments to companies active in the EU, including in...